

Emre Demirci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5452756/publications.pdf>

Version: 2024-02-01

39
papers

1,145
citations

623734

14
h-index

501196

28
g-index

39
all docs

39
docs citations

39
times ranked

1597
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-therapeutic dosimetry of normal organs and tissues of ¹⁷⁷ Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1976-1983.	6.4	166
2	⁶⁸ Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1461-1462.	6.4	127
3	Normal distribution pattern and physiological variants of ⁶⁸ Ga-PSMA-11 PET/CT imaging. <i>Nuclear Medicine Communications</i> , 2016, 37, 1169-1179.	1.1	126
4	Evaluation of PSMA PET/CT imaging using a ⁶⁸ Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. <i>Nuclear Medicine Communications</i> , 2015, 36, 582-587.	1.1	125
5	Comparison of ⁶⁸ Ga-DOTATATE and ⁶⁸ Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1271-1277.	6.4	119
6	The accuracy of ⁶⁸ Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1806-1812.	6.4	89
7	Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?. <i>Nuclear Medicine Communications</i> , 2019, 40, 86-91.	1.1	83
8	^{Lu-177} -PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. <i>Molecular Imaging and Radionuclide Therapy</i> , 2017, 26, 62-68.	0.7	53
9	¹⁷⁷ Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 2018, 39, 789-796.	1.1	53
10	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. <i>Nuclear Medicine Communications</i> , 2017, 38, 149-155.	1.1	32
11	Imaging Cancer-Associated Fibroblasts (CAFs) with FAPI PET. <i>Biomedicines</i> , 2022, 10, 523.	3.2	32
12	Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 1084-1089.	1.1	22
13	Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria. <i>Nuclear Medicine Communications</i> , 2020, 41, 759-767.	1.1	16
14	Post-therapy imaging of ²²⁵ Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2711-2712.	6.4	15
15	Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 2013, 34, 727-732.	1.1	14
16	Preclinical Evaluation of ¹⁸ F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors. <i>Molecular Imaging</i> , 2017, 16, 153601211668594.	1.4	14
17	The role of ⁶⁸ Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma. <i>Nuclear Medicine Communications</i> , 2017, 38, 76-83.	1.1	11
18	Assessment of Early Therapy Response with ¹⁸ F-FLT PET in Glioblastoma Multiforme. <i>Clinical Nuclear Medicine</i> , 2014, 39, e431-e432.	1.3	8

#	ARTICLE	IF	CITATIONS
19	ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM 68Ga-PSMA-11 PET SCANâ€. Radiation Protection Dosimetry, 2018, 182, 518-524.	0.8	8
20	Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT. Clinical Nuclear Medicine, 2017, 42, e504-e505.	1.3	6
21	Clinical Impact of Lower-Limb Imaging in ⁶⁸ Ga-PSMA PET/CT for Patients with Prostate Cancer. Journal of Nuclear Medicine Technology, 2019, 47, 233-237.	0.8	6
22	[68Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4523-4524.	6.4	4
23	Dual false positive of 68Ga-DOTA-TATE PET/CT scan in a patient with a history of pancreatic neuroendocrine tumor: A case report. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 133-135.	0.0	2
24	Myelodysplastic Syndrome Presenting With Diffuse Bone Marrow Uptake on 68Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2020, 45, 330-333.	1.3	2
25	F-18 FDG PET/CT Practice Guideline in Oncology. , 2020, 6, 339-357.		2
26	Procedure Guideline for Lymphoscintigraphy and Sentinel Lymph Node: Malignant Melanoma. , 2020, 6, 307-320.		2
27	The Role of 68GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy. Urology Journal, 2020, 18, 58-65.	0.4	2
28	Almost Complete Response with a Single Administration of ²²⁵ Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary. Molecular Imaging and Radionuclide Therapy, 2022, 31, 139-141.	0.7	2
29	Parasitic Infestation Mimicking Hepatic Metastasis with Four Different Imaging Modalities in a Patient with Breast Carcinoma. Breast Journal, 2017, 23, 468-470.	1.0	1
30	Procedure Guidelines for Lu-177 PSMA Radyoligand Treatment. , 2020, 6, 385-396.		1
31	Procedur Guideline for Prostate Cancer Imaging: Ga68 PSMA PET/CT. , 2020, 6, 370-384.		1
32	Clinical, pathological and (18)F-FDG PET/CT findings in synchronous primary vaginal and endometrial cancers. Hellenic Journal of Nuclear Medicine, 2016, 19, 170-2.	0.3	1
33	MP20-15 THE ACCURACY OF 68GALLIUM-PSMA PET/CT IN PRIMARY LYMPH NODE STAGING FOR HIGH RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	0
34	PET/CT in Treatment Response Evaluation of Colorectal Cancer. , 2021, 7, 241-245.		0
35	F-18 FDG PET/CT Practice Guideline in Oncology: Assesment of Treatment Response. , 2020, 6, 358-369.		0
36	Practical Guidance on Peptide Receptor Radionuclide Therapy. , 2020, 6, 406-415.		0

#	ARTICLE	IF	CITATIONS
37	Guideline for PET/CT Imaging of Neuroendocrine Neoplasms with 68Ga-DOTA-conjugated Somatostatin Receptor Targeting Peptides. , 2020, 6, 397-405.		0
38	Procedur Guideline for Lymphoscintigraphy and Sentinel Lymph Node in Breast Cancer. , 2020, 6, 321-338.		0
39	PRRT in NETs: Lu-177 PRRT and New Scope Alpha Treatment. , 2021, 7, 300-309.		0